Legal & General Group’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.75M | Sell |
63,294
-1,943
| -3% | -$125K | ﹤0.01% | 1611 |
|
|
2026
Q1 | $3.68M | Sell |
65,237
-10,696
| -14% | -$697K | ﹤0.01% | 1655 |
|
|
2025
Q4 | $6.09M | Sell |
75,933
-5,812
| -7% | -$390K | ﹤0.01% | 1456 |
|
|
2025
Q3 | $3.98M | Sell |
81,745
-4,454
| -5% | -$276K | ﹤0.01% | 1690 |
|
|
2025
Q2 | $6.43M | Buy |
86,199
+3,200
| +4% | +$212K | ﹤0.01% | 1423 |
|
|
2025
Q1 | $5.27M | Sell |
82,999
-1,961
| -2% | -$133K | ﹤0.01% | 1494 |
|
|
2024
Q4 | $6.63M | Buy |
84,960
+2,827
| +3% | +$227K | ﹤0.01% | 1422 |
|
|
2024
Q3 | $6.6M | Buy |
82,133
+745
| +0.9% | +$60.2K | ﹤0.01% | 1434 |
|
|
2024
Q2 | $6.73M | Buy |
81,388
+253
| +0.3% | +$22.3K | ﹤0.01% | 1362 |
|
|
2024
Q1 | $6.92M | Buy |
81,135
+1,148
| +1% | +$90.1K | ﹤0.01% | 1343 |
|
|
2023
Q4 | $6.84M | Sell |
79,987
-1,020
| -1% | -$88.2K | ﹤0.01% | 1355 |
|
|
2023
Q3 | $7.26M | Buy |
81,007
+1,301
| +2% | +$116K | ﹤0.01% | 1236 |
|
|
2023
Q2 | $6.79M | Buy |
79,706
+1,199
| +2% | +$101K | ﹤0.01% | 1286 |
|
|
2023
Q1 | $6.5M | Buy |
78,507
+887
| +1% | +$71.8K | ﹤0.01% | 1288 |
|
|
2022
Q4 | $6.1M | Buy |
77,620
+406
| +0.5% | +$32.6K | ﹤0.01% | 1296 |
|
|
2022
Q3 | $5.72M | Sell |
77,214
-1,170
| -1% | -$84K | ﹤0.01% | 1302 |
|
|
2022
Q2 | $5.11M | Buy |
78,384
+4,439
| +6% | +$263K | ﹤0.01% | 1397 |
|
|
2022
Q1 | $4.67M | Buy |
73,945
+232
| +0.3% | +$12.6K | ﹤0.01% | 1552 |
|
|
2021
Q4 | $3.91M | Buy |
73,713
+160
| +0.2% | +$9.75K | ﹤0.01% | 1699 |
|
|
2021
Q3 | $5.19M | Buy |
73,553
+9,290
| +14% | +$586K | ﹤0.01% | 1531 |
|
|
2021
Q2 | $4.28M | Sell |
64,263
-50,986
| -44% | -$3.61M | ﹤0.01% | 1615 |
|
|
2021
Q1 | $12.8M | Buy |
115,249
+603
| +0.5% | +$74.6K | ﹤0.01% | 1061 |
|
|
2020
Q4 | $13.6M | Sell |
114,646
-17,525
| -13% | -$1.89M | 0.01% | 970 |
|
|
2020
Q3 | $11.5M | Buy |
132,171
+9,962
| +8% | +$871K | 0.01% | 954 |
|
|
2020
Q2 | $10.9M | Buy |
122,209
+29,521
| +32% | +$2.98M | 0.01% | 953 |
|
|
2020
Q1 | $9.24M | Sell |
92,688
-1,406
| -1% | -$152K | 0.01% | 934 |
|
|
2019
Q4 | $10.8M | Buy |
94,094
+7,882
| +9% | +$954K | 0.01% | 989 |
|
|
2019
Q3 | $10.9M | Buy |
86,212
+696
| +0.8% | +$88.3K | 0.01% | 950 |
|
|
2019
Q2 | $10.3M | Buy |
85,516
+26,181
| +44% | +$2.58M | 0.01% | 957 |
|
|
2019
Q1 | $5.19M | Buy |
59,335
+879
| +2% | +$79.9K | ﹤0.01% | 1147 |
|
|
2018
Q4 | $5.85M | Buy |
58,456
+2,579
| +5% | +$271K | ﹤0.01% | 992 |
|
|
2018
Q3 | $6.4M | Sell |
55,877
-722
| -1% | -$74.7K | ﹤0.01% | 1042 |
|
|
2018
Q2 | $5.08M | Sell |
56,599
-54,381
| -49% | -$4.59M | ﹤0.01% | 1108 |
|
|
2018
Q1 | $8.11M | Buy |
110,980
+5,063
| +5% | +$347K | 0.01% | 886 |
|
|
2017
Q4 | $6.15M | Buy |
105,917
+959
| +0.9% | +$50.5K | ﹤0.01% | 974 |
|
|
2017
Q3 | $4.7M | Buy |
104,958
+5,065
| +5% | +$210K | ﹤0.01% | 1073 |
|
|
2017
Q2 | $3.94M | Buy |
99,893
+8,543
| +9% | +$351K | ﹤0.01% | 1128 |
|
|
2017
Q1 | $3.71M | Buy |
91,350
+733
| +0.8% | +$28.6K | ﹤0.01% | 1105 |
|
|
2016
Q4 | $3.64M | Buy |
90,617
+42,084
| +87% | +$1.59M | ﹤0.01% | 1025 |
|
|
2016
Q3 | $1.75M | Buy |
48,533
+35,559
| +274% | +$1.22M | ﹤0.01% | 1129 |
|
|
2016
Q2 | $372K | Buy |
12,974
+1,336
| +11% | +$40.4K | ﹤0.01% | 1486 |
|
|
2016
Q1 | $404K | Buy |
11,638
+759
| +7% | +$24.5K | ﹤0.01% | 1406 |
|
|
2015
Q4 | $354K | Buy |
10,879
+921
| +9% | +$29.9K | ﹤0.01% | 1464 |
|
|
2015
Q3 | $320K | Hold |
9,958
| – | – | ﹤0.01% | 1461 |
|
|
2015
Q2 | $413K | Buy |
9,958
+913
| +10% | +$38.5K | ﹤0.01% | 1382 |
|
|
2015
Q1 | $407K | Buy |
9,045
+1,687
| +23% | +$70.5K | ﹤0.01% | 1347 |
|
|
2014
Q4 | $285K | Sell |
7,358
-155
| -2% | -$5.68K | ﹤0.01% | 1403 |
|
|
2014
Q3 | $262K | Buy |
+7,513
| New | +$268K | ﹤0.01% | 1378 |
|
Other funds holding HAE
AI
Legal & General Group's HAE Position: Q2 2026 in Review
Legal & General Group reduced its Haemonetics (HAE) stake by 3% in Q2 2026, selling an estimated $125K and leaving 63,294 shares worth $4.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1611.
Legal & General Group first reported a position in HAE in Q3 2014 and has held it in 48 quarters since. The position peaked at $13.6M in Q4 2020. 329 funds tracked by Wall St. Rank hold HAE as of Q2 2026.
- Legal & General Group held 63,294 shares of Haemonetics worth $4.75M as of Q2 2026.
- Legal & General Group sold 1,943 Haemonetics shares in Q2 2026, an estimated $125K.
- Haemonetics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #1611 holding.
- Legal & General Group first reported a position in Haemonetics in Q3 2014 and has held it in 48 quarters since.
- Legal & General Group's Haemonetics position peaked at $13.6M in Q4 2020.
- 329 funds tracked by Wall St. Rank held Haemonetics as of Q2 2026.
Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.